How to Cite:
Sadeq, V. Q., Khalaf, H. M., Mohammed, M. A., & Abdulkafi, A. Q. (2022). Role of palivizumab in prophylaxis of bronchiolitis caused by respiratory syncytial virus. *International Journal of Health Sciences*, *6*(S1), 12464–12476. https://doi.org/10.53730/ijhs.v6nS1.8091

Role of palivizumab in prophylaxis of bronchiolitis caused by respiratory syncytial virus

Dr. Vian Qader Sadeq
F.I.C.M.S(Ped), M.B.Ch.B, Kirkuk general hosp
Email: Vianqs2000@gmail.com

Dr. Huda Mohammed Khalaf
MBChB F.I.B.M.S, Azady teaching hospital
Email: Hudamohamed130@gmail.com

Dr. Mustafa Abdalwahid Mohammed
MBChB DCH, Al.Duloyia General Hospital
Email: Mustafahujazi@gmil.com

Dr. Ali Qais Abdulkafi
MBChB DCH, Kirkuk general hospital
Email: Newiraqhospital@yahoo.co.uk

***Abstract*---**Infections with respiratory syncytial virus (RSV) are common. the most common causes of life-threatening respiratory illnesses medical treatment in the form of intensive care in some circumstances. Once .Resolved, there may be variable respiratory consequences severity. Aim: illustrate Palivizumab's ability to protect against disease of infection with the respiratory syncytial virus

***Keywords*---**Syncytial virus of the lungs, Palivizumab, Preterm, Cytokines.

Introduction

Virology's essentials

It was determined that the respiratory syncytial virus (RSV) in a monkey for the first time in 1955. The virus is a parasite in the human body. In 1957, two neonates with a congenital condition known as An infection of the airways [1]. It is a member of the Monegavirales order and the Paramyxoviridae family. genus Pneumovirus belongs to the Pneumovirinae subfamily. Helical symmetrical virion is the RSV virion. enclosed in a lipid membrane, the nucleus has three

transmembrane membranes and is derived from the host cellular spiky-shaped glycoproteins on its surface surface. Despite the fact that glycoprotein G is the mediating factor, adheres to the airway's ciliated epithelium It is not essential for RSV to enter the infected cell. but not enough to induce the illness. A total of two antigens exist Identification of RSV subgroups A and B based on glycoprotein G's various conformations As an alternative, the protein's sequence is preserved in both of these subgroups: plays an important function in facilitating viral spread the viral envelope is fusioned to allow entry into cells with the membrane of the cytoplasm. Protein three is a Proteins termed SH are a type of viroporin. capable of altering the permeability of cell membranes [2]. As soon as RSV has entered the host cell, proteins G and F (viral genome transcription and replication) proteins are involved in viral replication in the cytoplasm. 15–20 hours later, the virus's RNA concentration had peaked. infection has occurred It is possible that the virus is now reproducing itself. must be liberated from the cell and last for about Or until the cell is entirely depleted. destroyed. This phase may be preceded by the previous phase. (major) development of cytopathogenic syncytia in cells impact of the infection)

Long-term effects, epidemiology, and clinical aspects complications

RSV is the most common cause of airway infections among children. young children, and bronchiolitis is a disease during the first year of life, the most common cause of hospitalization of life (around one percent of European and American youngsters) Hospitalization in the United States peaks at 2 months.

In terms of age [4]. Infants under the age of three months for whose risk factors (prematurity, bronchopulmonary disease) already present dysplasia, congenital heart disease, immunodeficiency, and other conditions those suffering from neuromuscular illnesses severely ill and in need of hospitalization, at times for placement in the critical care unit. In the modernized world, bronchiolitis, a viral infection that occurs in countries, The first year of a child's existence is still quite significant. how the person died [5]. Between the months of May and September,. has an epidemic. There is a surge in January and February, which is November and March. Epidemiology research in Italy have demonstrated this [6].

Clinical signs and symptoms are used to make the diagnosis of bronchiolitis. rhinorrhea and/or an infection of the upper respiratory tract, a first respiratory distress episode accompanied with crackles and/or breathing difficulties, including wheezing and polypnea the inability to take water or meals, hypoxia [7–9]. If a child has acute bronchiolitis, they may present with the following symptoms: ranges from a wide variety of clinical conditions any degree of respiratory difficulty, from minor to imminent, failure. Response of the body to RSV infection bronchiolitis in children is marked by A substantial neutrophil-induced inflammation is present. the bronchial tubes. In cases of bronchiolitis, hospitalization is recommended. hypoxia (O2 saturation 90-92 percent under ambient conditions) is present a lack of oxygen in the blood, significant respiratory discomfort, and dehydration apnea. Other factors to consider are postnatal age, as well as gestational and postnatal ages that fall under categories at danger, an aberrant state of consciousness. decreased fluid intake (less than 50%) and responsiveness habitual consumption, as well as negative social and

environmental consequences factors. Acute bronchiolitis in neonates or babies. are in need of hospitalization and admission to an ICU for children exhibiting significant impairment and respiratory failure of the general conditions [9]. Many of the treatments have not been proven to be effective. bronchodilators, etc.) are routinely used to treat bronchiolitis. anti-inflammatory drugs such as corticosteroids, and antibiotics (warm, humidified, high-flow oxygen, and hydration) still the strategy advocated by the most prominent There are rules from throughout the world and in the US. There have been a number of recent studies I've read that nebulization with 3.0% sodium chloride is an effective treatment. however, there is data to suggest that it has a clinical advantage Contrasting views [10–13] are expressed. Adrenaline nebulized into the lungs may be valuable in the hospital as a rescuer in a life-threatening condition [8]. The absence of viable therapeutic options for the disease. Bronchitis and the absence of RSV vaccinations worsen this problem. prevention's involvement in reducing the severity of this ailment. Consistent management of infection can be achieved with the use of environmental, sanitary and hygienic precautions the infection to a minimum and relying solely on pharmacological vaccination with palivizumab during the course of the illness epidemic season to vulnerable youngsters [14, 15]. Environmental prophylaxis, particularly during the epidemic season, is essential. decreases the risk of RSV transmission in healthcare facilities

The long-term effects of bronchiolitis on the lungs

Babies at risk of developing respiratory syndrome virus infection (RSV) hospitalization may interfere with normal daily activities. the immunological and respiratory systems' growth and potentially linked to an increased risk of repeat Preschoolers with asthma and bronchospasm School-aged children's respiratory health. As a result of recent follow-up investigations, Young adults (18 and 30 years old) have shown that up among those who had previously been hospitalized, 30-40% Asthma is brought on by bronchiolitis. and take asthma medication. A recently completed randomized, double-blind, placebo-controlled a study found that palivizumab could be used as a preventative measure. kids born at 33 to 35 weeks gestation (gestational age) age) is able to reduce the number of people by 61% breathing problems for the first year of his life, therefore corroborating the idea that there was direct injury.

Palivizumab

Medimmune, Inc.'s Palivizumab (Synagis; Gaithersburg) An IgG1 monoclonal antibody (MD) is a humanized version of this antibody. in the form of a recombinant DNA vaccine, created an epitope in the fusion F protein's A antigenic location It works by preventing and neutralizing the fusion of RSV. Palivizumab Thus, viral replication is prevented by the F protein's function. Randomized, double-blind, controlled study at many sites Impact (RSV-IMpact trial) has been licensed in the United States In 1998, palivizumab was delivered at a dosage of 15 mg/kg. once a month via injection into the muscle. for a total of five administrations during the epidemic season . Despite the fact that it has been in widespread usage for over a decade, Only a recent study by Robbie et al. is relevant. examined a variety of pharmacokinetic models palivizumab in newborns, children, and adults with a number of different conditions presentations in the

therapeutic setting. The little pharmacokinetic studies that have been done so far Only mean serum concentrations were reported in the trials. 17 to 26.8 days for the half-life As far back as 2012, the manufacturing company stated that. a wide range of serum values between individuals when palivizumab is provided in accordance with the Recognized treatment plan Research by Robbie and colleagues [21] also evaluated the effect of the on the variability between individuals. An antidrug antibody (ADA), as well as several others testing to see if a proper treatment plan is in place for a certain disease With just three administrations, security was guaranteed. One dose out of a possible five The findings of the study. Intramuscular injections are given once a month. dosing regiment of 15 mg/kg daily for five months as per the recommendations in It would appear that a registered plan would be more appropriate.
[Level of evidence II – recommendation A's strength] Preterm newborns receive palivizumab as a preventative.

Table 1
Recommendation summary table

	Level of evidence	Strength of recommendation
Environmental hygiene prevention	II	A
Efficacy and safety of palivizumab prevention	II	A
Dose of 15 mg/Kg once a month for 5 months	II	A
Prophylaxis in subjects with <29 weeks GA and aged ≤ 12 months at the beginning of epidemic season	II	A
Prophylaxis in subjects with 29–35 weeks GA and aged ≤ 6 months at the beginning of epidemic season	IV	B
Palivizumab prophylaxis in infants with bronchopulmonary dysplasia and aged ≤ 12 months at the beginning of epidemic season, and during the second year of life in children who require medical therapy II A	II	A

Prophylaxis in infants with severe congenital heart disease and aged ≤ 12 months at the beginning of epidemic season		
Prophylaxis in infants with cystic fibrosis, Down syndrome, congenital diaphragmatic hernia, neuromuscular diseases, immunodeficiency, accumulation disorders, esophageal atresia, lung transplantation	V	B

Methods
Design of the investigation

Palivizumab prophylaxis has a new set of age criteria. Health Ministry regulations, a long-term research preterm born between 2019 and 2021 were chosen for this honor. the intended audience. The neonatal intensive care unit's (NICU) medical records were Scanned for newborns who met the study's inclusion and exclusion criteria, respectively. Below, you will find a detailed explanation. Premature infants born at 29–32 weeks gestation In 2019–2021, WGA members must be at least 5 years old. Any mechanical ventilation lasting longer than 24 hours is a disqualifier. congenital abnormalities (i.e. cystic fibrosis) and chronic illnesses (i.e. CF). recognized immune insufficiency) or congenital cardiac disease. Methylcholine challenge is the primary method for measuring AHR. Serum inflammatory cytokines (MCT) in children born between 29 and 32 weeks WGA who received Palivizumab and are currently being treated a person who has reached the age of majority. a secondary goal is to measure eosinophil counts and other allergy markers serum immunoglobulin E (IgE) concentration and exhaled fractional concentration children born at high risk of respiratory morbidity have elevated levels of nitric oxide (FeNO). Palivizumab was given to 29–32 WGA, and they are currently Over the age of five. Evaluation: All children were assessed while they were between the ages of five and seven, because Spirometry, MCT, and other tests that require teamwork must be completed with the cooperation of all participants. FeNO assays are performed. One day before the visit, the families were contacted. certain that their children were in good health and had not received systemic steroids treatment for at least two weeks before beginning classes. Every single one of the kids had their health checked up. the opinion of a doctor. a survey on respiratory health that included questions about symptoms and medicine demands have been met by their legal status since birth. guardian. In accordance with the American Thoracic Society, spirometry was carried out. For the American Thoracic Society (ATS) and the European Respiratory Society (ERS) KoKo spirometer (nSpire Healthcare) for pre-school children [18] Longmont, Colorado-based Inc. Data on the FEV curves was collected. taking advantage of the program's reward targets. The experiments were conducted with Nasal clips

are worn by participants. Repeated base moves were carried out. until the finest possible visual effort has been made on at least one level. Three FEV curves that are technically acceptable. AHR was evaluated by MCT [19,20]. The test was successfully completed. Wherever you want. The investigation team and a parent were present. throughout the test, if necessary. According to plan, the test was carried out. Triple doses of fresh methacholine have been recommended in published guidelines [21,22]. The solution (0.057–13.925 mg/mL), administered via a dosimeter (KoKo). Inc.), using a mouthpiece in accordance with the instructions provided by the manufacturer With a nose ring or a chin band. The kids were told to take a few long breaths to calm themselves down. While erect, with one's back straight. Between doses, there was a 5-minute lag time. Also, a second set of spirometry was done on the patient. An FEV reduction of 20% after a deviation of one minute (FEV1) from the initial values, it was deemed that putting one's knowledge to the test The nebulized albuterol (2.5 mg) was delivered at this stage. The specific amount of methacholine that triggered a reaction. The software calculated a 20 percent decrease in FEV1 (PC20 value) based on the following in accordance with the standards, log-transformed formula

Exercise challenge testing [22] for methacholine. In this study, FeNO levels (fractional exhaled nitric oxide) were employed as a measurement eosinophilic inflammation in the airways Measuring the size An FeNO analyzer was used to measure fractional exhaled NO (ECO Medics) on the basis of advice from the ATS [24]. Tests for Eosinophil count and IgE serum levels were performed on the patient. In case further testing was necessary, additional serum samples were kept frozen at 20 °C. cytokines indicative of inflammation Interleukins (IL) 4 and 5 levels Immunoglobulins 13 and 12, interferon gamma, TNF-alpha, and interferon gamma IL6, IL17, and granulocyte-colony stimulating factor are all examples of (TNF-) molecules (G-CSF), transforming growth factor-beta (TGF-), interleukin-2 (IL-2), and interleukin-10 (IL-10) were found in serum. based on results from Multi-analyte ELISArray kits (MEH-003A, QIAGEN), as described in according to the guidelines provided by the product's creators.

Analysis of statistical data

Premature infants with a gestational age of 29–32 WGA were analyzed. during the years of 2019 and 2021. In the process of preparing for the event, We estimated that 25% of the youngsters would not be able to participate in the study. 25 percent of the participants would not meet the study's eligibility criteria. A total of 84 patients were selected for each subgroup. in order to find the 0.5 standard deviation of airway hypersensitivity for a two-way comparison Sided tail. Comparisons were made between demographic data and base values. Fisher's exact test and one-way analysis of variance for quantitative variables categorical variables should be tested. A p value of 0.05 or lower was judged significant.

Results

More than 80 percent of the parents of the 294 children who were eligible for the research accepted the invitation to participate: 30 of them had not. those who had received the Palivizumab prophylactic (P-group) Group of people.

Table 1
Shows the demographics of the participants in the study

	Palivizumab (−) N=30	Palivizumab (+) N = 54	p-value
a person's chronological age (yrs)	5.6 ± 0.5	5.6 ± 0.86	NS
Sexuality (boys)	18 (60%)	36 (67%)	NS
When a woman is pregnant (wks) Gestational	31.04 ± 0.59	30.3 ± 0.91	0.004
a baby's starting weight (g)	1548.3 ± 243.6	1322.8 ± 228.6	0.008
steroid administered to unborn children treatment	20 (67%)	52 (96%)	0.016
The delivery was unplanned.	14 (47%)	42 (78%)	0.085
Treatment with surfactant	2 (7%)	16 (29%)	0.12
Ventilation that isn't intrusive	16 (53%)	44(81%)	0.07
Supplementation with oxygen	6 (1–4.25)	10 [1–18]	0.17
The time spent in the neonatal intensive care unit (NICU) (d)	43.3 ± 4.6	49.2 ± 9.1	0.018

Data are presented as mean ±SD, number (percentage) or median (25% - 75%).
NICU Neonatal intensive care unit.

Table 2
Spirometry and MCT results in children who received and did not receivePalivizumab

Spirometry	Palivizumab (−) N=30	Palivizumab (+) N = 54	p-value
FEV1 (L/sec)	1.17 ± 0.21	1.12 ± 0.22	0.34
FEV1%predicted	84.1 ± 18.3	86.5 ± 10.7	0.57
FEV1/FVC	0.92 (0.90–0.99)	0.94 (0.90–0.99)	0.73
FEV1/FVC %predicted	110.1 ± 5.8	107.6 ± 7.8	0.32
FEF25-75% (L)	1.3 ± 0.31	1.4 ± 0.38	0.22
FEF25-75%predicted	90.0 ± 22.5	90.2 ± 22.6	0.97
PEFR (L/m)	2.5 ± 0.37	2.3 ± 0.54	0.18
PEFR %predicted	74.0 ± 15.8	76.5 ± 13.6	0.57

Table 3
Children with respiratory parameters who received Palivizumab and those who did not

Symptoms	Palivizumab (−) N=30	Palivizumab (+) N = 54	p-value
Repeated wheezing.	16 (53%)	34 (63%)	0.74
Coughing	18 (60%)	38 (70%)	0.52
a feeling of breathlessness	6 (20%)	28 (52%)	0.056
Wheezing in the middle of the night	10 (33%)	20 (37%)	1.00
Wheezing while exercise	6 (20%)	10 (19%)	1.00
Respiratory episodes>2 per year	16 (53%)	26 (48%)	1.00

patient withStridor	8 (27%)	26 (48%)	0.21
Repeated pneumonic infections	6 (20%)	4 (7%)	0.33
Inpatient care for respiratory issues	10 (33%)	14 (26%)	0.72
Asthma drugs have been prescribed to children since birth.			
Steroids administered throughout the body Systemic	14 (47%)	20 (37%)	0.74
Bronchodilators	16 (53%)	42 (78%)	0.16
Inhalation of steroids	16 (53%)	32 (59%)	0.75
Montelukast	6 (20%)	14 (26%)	1.00
RSV has been proven to be infected.	2 (7%)	0	0.36
Snoring 0f patients	12 (40%)	4 (7%)	0.016

Table 4
shows the results. Analyses of the allergic/eosinophilic status of children who received and those who did not. Palivizumab

Subjective report (%)	Palivizumab (−) N=30	Palivizumab (+) N = 54	p-value
Atopic dermatitis	0	6 (1%)	p=0.54
Food allergy	6 (20%)	1	p=0.04
Rash	6 (20%)	8 (15%)	p=0.68
Family history of atopy	12 (40%)	32 (59%)	p=0.33
	8 (27%)	4 (7%)	p=0.16

Allergic rhinitis			
Objective evaluation			
Eosinophil count	(×10ˆ3/μL) 200 (100–390)	300 (150–535)	p=0.22
IgE serum level (IU/mL)	63.1 (20.5–164.5)	94.3 (32.3–154.5)	p=0.67
FeNO ppb	5.05 (2.97–6.45)	6.05 (3.8–13.4)	p=0.10

Data are presented as number (percentage) or median (25% - 75%).
IgE-immunoglobulin E; FeNO Fractioned exhaled nitric oxide.

Discussion

Neither AHR nor allergic/eosinophilic symptoms were different in this real-life experiment. indicators of inflammation after 5–7 years, comparing preterm and full-term Children born between 29 and 32 WGA who received Palivizumab and those who did not. Serum cytokines Th2 and Th17 were found to play a role in the etiology of the disease. The immunoprophylaxis group saw a decrease in asthma symptoms. The results of this short study challenge the long-term viability of the findings. Palivizumab has a positive effect. RSV immunoprophylaxis has already been studied in the long term. can reduce wheezing attacks, but there's no change in surveys and a single test to determine the prevalence of current asthma Spirometry measurements are made [14,15]. We looked at a number of variables, such as MCT, FeNO, and serum IgE. well as the quantity of eosinophils and the serum profile of inflammatory cytokines symptoms experienced, and the medications taken to treat those symptoms. Our primary goals are as follows: were AHR and serum cytokines. We evaluated AHR by MCT. In a high proportion of the children, positive MCT (PC20 < 8 mg/dl) was detected: 57.7 percent in the P+ group and 46.6 percent in the P- group. Similar results were recently reported by Prais et al. who compared children, mean age of 8.9 years, who were born preterm (< 29 WGA): 30 had received Palivizumab and 33 had not. The rates of positive MCT (PC20 < 4 mg/dl) were 62 percent and 65 percent, respectively, with no differences in spirometry values. Thus, both our study and theirs failed to demonstrate a long-term protective effect of Palivizumab on airway reactivity. Only limited data are available regarding MCT results in Five to six-year-old youngsters that were born at term are considered healthy. Because of this, whether the high rate of positive MCT is attributable to an increase in the number of MCT patients early onset of airway hyperresponsiveness due to preterm. Respiratory illness and medicine use, as documented in the literature The questionnaire did not reveal any differences between the two studies. More children were found to be allergic, according to Sigurs et al. [2]. than pre-RSV controls In our study, we found no difference. serum IgE, FeNO or blood eosinophil count. This is in agreement with what I've read. with the findings of another study that did not identify any change in Immunoprophylaxis recipients had higher levels of FeNO than those who did not. Some of the participants. The identical values in the two groups, of FeNO long-term protective effects of IgE and blood eosinophil levels are inconclusive. inducing an allergic/eosinophilic

response For the first time, a long-term immunomodulation study has been conducted. human response to RSV immunoprophylaxis. We preterm infants' cytokine profiles were studied in detail and between the ages of 5 and 7. We decided to investigate T helper type 1 (Th1) and T helper type 2 (Th2) cytokines in the blood Significant variations were discovered between the T helper type 2 (Th2) and 17 (Th17) lineages. Palivizumab recipients and those who did not receive it.
P+ children reported increased levels of IL4, IL5, and IL13 (Th2), which are markers of inflammation. and lower levels of levcytokines), as well as an increase in the three Th17 cytokines: interleukin 17 (IL17), G-CSF with IL16. Th17 has recently been implicated in RSV infection mortality. both in animal models and in humans has been a major area of study and is still a contentious subject. In spite of this, some research suggests that IL17. allows for less severe symptoms due to its protection against RSV infection. sickness and high levels of IL17 production are linked, according to other studies. asthma that is steroid-resistant and has a high neutrophil count asthma Larraaga et al. found that IL-17 was not present in the samples. detectable in the serum of healthy infants as opposed to children with the condition .

Conclusions

RSV infection can be prevented by using Palivizumab, a safe and well-tolerated Mab, as a preventative measure.when it comes to preterm and high-risk infantsAfter 35 weeks gestation, a baby can be considered a full-term infant.12 months), and those with bronchopulmonary dysplasia and pulmonary arterial hypertensioncongenital heart disease that is hemodynamically significant (up to)The age of 24 months (in terms of years). PredominantlyA total of five 15 mg/kg doses of palivizumab are administered intramuscularly.treatment was needed in some cases for RSV during the first season underlying condition (congenital bronchopulmonary dysplasia) over a second RSV, heart disease (prevention) may be given. season, as well as in certain clinically rare pathologic conditions Lung and neuromuscular impairments in cases of hypoplasia surgical procedures such as tracheostomies, etc.) palivizumab specialist. In light of the fact that the vast majority of RSV-related deaths occur in developing countries with limited access to resources are unable to prophylactic palivizumab because of the high price of the product There is little hope that palivizumab will have an impact on the global burden of disease of the RSV virus. As far as a vaccine is concerned, there is none to be found. Antiviral treatment for RSV is simple and effective, and RSV prophylaxis is available. Only palivizumab injections remain as a viable treatment option. RSV infection in high-risk children can be prevented.

Recommendations

In spite of the small sample size and demographic differences, differences between the two groups make it impossible to draw conclusions. and call for long-term studies to be carried out the evidence suggests that the following suggestions should be re-evaluated every three to five years upcoming studies.

References

1. Anderson LJ, Barney S. Graham Editors Challenges and Opportunities for Respiratory Syncytial Virus Vaccines. Berlin Heidelberg: Springer-Verlag; 2013.
2. Collins PL, Melero J. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus rev. 2011;62:80–99.
3. Mastrangelo P, Hegele RG. Host and viral factors in respiratory syncytial virus infection. Curr Pediatr Rep. 2013;1:149–57.
4. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360:588–98.
5. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375:1545–55.
6. Medici MC, Arcangeletti MC, Rossi GA, Lanari M, Merolla R, Paparatti UD, et al. Four year incidence of respiratory syncytial virus infection in infants and young children referred to emergency departments for lower respiratory tract diseases in Italy: the “Osservatorio VRS” Study (2000–2004). New Microbiol. 2006;9:35–43.
7. Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134:e1474–502.
8. Zorc JJ, Hall CB. Brochiolitis: Recent evidence on diagnosis and management. Pediatrics. 2010;125:342–9.
9. Baraldi E, Lanari M, Manzoni P, Rossi GA, Vandini S, Rimini A, et al. Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants. Ital J Pediatr. 2014;40:65. http://www.ijponline.net/content/40/1/65.
10. Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP. Nebulised hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev. 2013;7:CD006458. doi:10.1002/14651858.CD006458.
11. Everard ML, Hind D, Ugonna K, Freeman J, Bradburn M, Cooper CL, et al. SABRE: a multicentre randomised control trial of nebulised hypertonic saline in infants hospitalised with acute bronchiolitis. Thorax 2014;69:1105–12.
12. Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV) Lina Bollani1, Eugenio Baraldi2, Gaetano Chirico3, Andrea Dotta4, Marcello Lanari5, Antonello Del Vecchio6,Paolo Manzoni7, Antonio Boldrini8, Piermichele Paolillo9, Sandra Di Fabio10, Luigi Orfeo11, Mauro Stronati12, Costantino Romagnoli13,14
13. POLICY STATEMENTUpdated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Riskof Hospitalization for Respiratory Syncytial Virus Infection, Organizational Principles to Guide and Define the ChildHealth Care System and/or Improve the Health of all Children
14. Long term follow-up of Palivizumab administration in children born at 29–32 weeks of gestation Ronen Bar-Yosepha, Julie Haddadb, Monnera Hannaa, Irena Kesselc, Amir Kugelmanb,d, Fahed Hakima,d,e,1, Lea Bentura

15. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection, ISSN: 2164-5515 (Print) 2164-554X (Online) Journal homepage: https://www.tandfonline.com/loi/khvi20
16. Respiratory syncytial virus: diagnosis, prevention and management Rachael Barr, Christopher A. Green, Charles J. Sande and Simon B. Drysdale, *Ther Adv Infectious Dis* 2019, Vol. 6: 1–9 DOI: 10.1177/ 2049936119865798
17. Palivizumab for the prevention of respiratory syncytial virus infection Alexander L. Rogovik MD PhD Bruce Carleton PharmD Alfonso Solimano MD Ran Goldman MD FRCPC
18. E.A. Simoes, Respiratory syncytial virus infection, Lancet 354 (1999) 847–852.
19. N. Sigurs, R. Bjarnason, F. Sigurbergsson, et al., Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7, Am. J. Respir. Crit. Care Med. 161 (2000) 1501–1507
20. N. Sigurs, R. Bjarnason, F. Sigurbergsson, et al., Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls, Pediatrics 95 (1995) 500–505
21. N. Sigurs, P.M. Gustafsson, R. Bjarnason, et al., Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13, Am. J. Respir. Crit. Care Med. 171 (2005) 137–141.